RESUMEN
BACKGROUND: There is near-global consensus that all newborns be given parenteral vitamin K1 (VK1 ) at birth as prophylaxis against VK deficiency bleeding (VKDB). Breastmilk has a low VK content and cases of late VKDB are reported in exclusively breastmilk-fed preterm infants despite VK prophylaxis at birth. OBJECTIVES: To assess the prevalence of functional VK insufficiency in preterm infants based on elevated under-γ-carboxylated (Glu) species of Gla proteins, factor II (PIVKA-II), and osteocalcin (GluOC), synthesized by liver and bone, respectively. PATIENTS/METHODS: Prospective, multicenter, observational study in preterm infants born <33 weeks' gestation. Blood samples and dietary history were collected before hospital discharge, and after discharge at 2-3 months' corrected age. Outcome measures were serum VK1 , PIVKA-II, and %GluOC (GluOC as a percentage of the sum of GluOC plus GlaOC) compared between exclusively breastmilk-fed and formula/mixed-fed infants after discharge. RESULTS: After discharge, breastmilk-fed babies had significantly lower serum VK1 (0.15 vs. 1.81 µg/L), higher PIVKA-II (0.10 vs. 0.02 AU/ml) and higher %GluOC (63.6% vs. 8.1%) than those receiving a formula/mixed-feed diet. Pre-discharge (based on elevated PIVKA-II), only one (2%) of 45 breastmilk-fed infants was VK insufficient. After discharge, eight (67%) of 12 exclusively breastmilk-fed babies were VK insufficient versus only one (4%) of 25 formula/mixed-fed babies. CONCLUSIONS: Preterm infants who remain exclusively or predominantly human breastmilk-fed after neonatal unit discharge are at high risk of developing subclinical VK deficiency in early infancy. Routine postdischarge VK1 supplementation of breastfed infants to provide intakes comparable to those from formula milks should prevent this deficiency.
Asunto(s)
Leche Humana , Deficiencia de Vitamina K , Lactante , Recién Nacido , Humanos , Recien Nacido Prematuro , Cuidados Posteriores , Estudios Prospectivos , Alta del Paciente , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/epidemiología , Deficiencia de Vitamina K/prevención & control , Vitamina K 1 , Hemorragia , Vitamina KRESUMEN
BACKGROUND: The development of coagulation disorders can be dangerous and fatal in the older people, especially those with multiple medical conditions. Vitamin K-dependent coagulation disorders are easily overlooked when anticoagulant drugs are not used and the patient shows no signs of bleeding. CASE PRESENTATION: We report a case of a 71-year-old male suffering from pulmonary infection with severe coagulation disorder without bleeding symptoms. He also had a history of Parkinson's disease, Alzheimer's disease and cardiac insufficiency. Coagulation tests were normal at the time of admission, prothrombin time (PT) is 13.9 (normal, 9.5-13.1) seconds and the activated partial thromboplastin time (APTT) is 30.2 (normal, 25.1-36.5) seconds. But it turned severely abnormal after 20 days (PT: 136.1 s, APTT: 54.8 s). However, no anticoagulants such as warfarin was used and no bleeding symptoms were observed. Subsequent mixing studies with normal plasma showed a decrease in prothrombin times. Vitamin K deficiency was thought to be the cause of coagulation disorders considering long-term antibiotic therapy, especially cephalosporins, inadequate diet and abnormal liver function. After supplementation with 20 mg of vitamin K, coagulation dysfunction was rescued the next day and serious consequences were effectively prevented. CONCLUSIONS: Overall, timely vitamin K supplementation with antimicrobials that affect vitamin K metabolism requires clinician attention, especially in older patients who are multimorbid, frail or nutritionally compromised, and are admitted to hospital because of an infection that needs antimicrobial therapy are at risk of clotting disorders due to abnormal vitamin K metabolism secondary to altered gut flora, which can exacerbate existing nutritional deficiencies.
Asunto(s)
Trastornos de la Coagulación Sanguínea , Neumonía , Deficiencia de Vitamina K , Anciano , Anticoagulantes/farmacología , Anticoagulantes/uso terapéutico , Coagulación Sanguínea , Trastornos de la Coagulación Sanguínea/diagnóstico , Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Trastornos de la Coagulación Sanguínea/etiología , Humanos , Masculino , Neumonía/complicaciones , Vitamina K , Deficiencia de Vitamina K/complicaciones , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/tratamiento farmacológicoRESUMEN
Vascular calcification (VC) is highly prevalent in Chronic Kidney Disease (CKD) patients, progresses gradually with deterioration of kidney function and is a strong, independent predictor of cardiovascular (CV) mortality. Matrix Gla Protein (MGP), the most potent inhibitor of VC, requires vitamin K as a co-factor to become biologically active. Accumulating epidemiological data have associated vitamin K depletion with VC progression and CV outcomes. CKD patients are characterized by poor vitamin K status and at the same time, pronounced CV calcification. In early and advanced CKD, including end-stage kidney disease, exogenous supplementation of vitamin K (especially with menaquinone 7, its most bioavailable form) might decrease the inactive form of MGP (dephosphorylated, uncarboxylated MGP) and probably retard the progression or even reverse VC. Here, we focus and discuss the interventional human studies of vitamin K supplementation in CKD patients and suggest future directions in this area of interest.
Asunto(s)
Insuficiencia Renal Crónica , Calcificación Vascular , Deficiencia de Vitamina K , Suplementos Dietéticos/efectos adversos , Femenino , Humanos , Masculino , Diálisis Renal/efectos adversos , Insuficiencia Renal Crónica/diagnóstico , Insuficiencia Renal Crónica/tratamiento farmacológico , Insuficiencia Renal Crónica/epidemiología , Calcificación Vascular/metabolismo , Vitamina K , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/tratamiento farmacológico , Deficiencia de Vitamina K/epidemiologíaRESUMEN
We report a probable case of abetalipoproteinemia in an infant who presented with unusual symptoms of late-onset vitamin K deficiency. Abetalipoproteinemia is a rare autosomal recessive disease caused by mutation of the microsomal triglyceride transfer protein gene, resulting in the absence of microsomal triglyceride transfer protein function in the small bowel. It is characterized by the absence of plasma apolipoprotein B-containing lipoproteins, fat malabsorption, hypocholesterolemia, retinitis pigmentosa, progressive neuropathy, myopathy, and acanthocytosis. A biopsy of the small intestine characteristically shows marked lipid accumulation in the villi of enterocytes. Large supplements of fat-soluble vitamins A, D, E, and K have been shown to limit neurologic and ocular manifestations. Dietary fat intake is limited to medium-chain triglycerides.
Asunto(s)
Abetalipoproteinemia/complicaciones , Deficiencia de Vitamina K/complicaciones , Abetalipoproteinemia/sangre , Abetalipoproteinemia/diagnóstico , Abetalipoproteinemia/patología , Duodeno/patología , Enterocitos/patología , Femenino , Humanos , Lactante , Recién Nacido , Deficiencia de Vitamina K/sangre , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/patologíaRESUMEN
Background: A low vitamin K status is common in patients on haemodialysis, and this is considered one of the reasons for the accelerated atherosclerosis in these patients. The vitamin is essential in activation of the protein Matrix Gla Protein (MGP), and the inactive form, dp-ucMGP, is used to measure vitamin K status. The purpose of this study was to investigate possible underlying causes of low vitamin K status, which could potentially be low intake, washout during dialysis or inhibited absorption capacity. Moreover, the aim was to investigate whether the biomarker dp-ucMGP is affected in these patients. Method: Vitamin K intake was assessed by a Food Frequency Questionnaire (FFQ) and absorption capacity by means of D-xylose testing. dp-ucMGP was measured in plasma before and after dialysis, and phylloquinine (vitamin K1) and dp-ucMGP were measured in the dialysate. Changes in dp-ucMGP were measured after 14 days of protein supplementation. Results: All patients had plasma dp-ucMGP above 750 pmol/L, and a low intake of vitamin K. The absorption capacity was normal. The difference in dp-ucMGP before and after dialysis was -1022 pmol/L (p < 0.001). Vitamin K1 was not present in the dialysate but dp-ucMGP was at a high concentration. The change in dp-ucMGP before and after protein supplementation was -165 pmol/L (p = 0.06). Conclusion: All patients had vitamin K deficiency. The reason for the low vitamin K status is not due to removal of vitamin K during dialysis or decreased absorption but is plausibly due to a low intake of vitamin K in food. dp-ucMGP is washed out during dialysis, but not affected by protein intake to a clinically relevant degree.
Asunto(s)
Ingestión de Alimentos/fisiología , Conducta Alimentaria/fisiología , Fenómenos Fisiológicos de la Nutrición/fisiología , Diálisis Renal , Deficiencia de Vitamina K/etiología , Vitamina K/administración & dosificación , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Proteínas de Unión al Calcio/sangre , Proteínas de la Matriz Extracelular/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Encuestas y Cuestionarios , Vitamina K/metabolismo , Deficiencia de Vitamina K/diagnóstico , Proteína Gla de la MatrizRESUMEN
BACKGROUND: An increase in serum undercarboxylated osteocalcin concentrations suggests vitamin K deficiency. Clinical intervention studies suggested that the vitamin K supplementation might contribute to preventing bone loss in postmenopausal women. Evidence on the relationship between serum undercarboxylated osteocalcin (ucOC) levels and bone parameters of quantitative ultrasound (QUS) is limited. We examined the correlation between serum ucOC concentrations and bone status as measured by QUS among middle-aged and older Japanese men and women. METHODS: The subjects were community-dwelling men (n = 358) and women (n = 503) aged ≥ 40 years in Japan. Heel QUS parameters, including the stiffness index, speed of sound, and broadband ultrasound attenuation, were measured. Serum ucOC concentrations were measured by electrochemiluminescence immunoassay. Grip strength was measured in the dominant hand. Information on alcohol drinking, current smoking, exercise, and menopause in women was collected. RESULTS: Serum ucOC concentrations were significantly associated with age in both sexes. Serum ucOC concentrations in men were higher at ≥ 80 years than those in the age groups of 40-49, 50-59, and 60-69 years. Serum ucOC concentrations in women were higher in the age groups of 50-59 and 60-69 years than those at 40-49 years. Partial correlation analysis adjusting for covariates (age, body mass index, grip strength, alcohol drinking, current smoking, and exercise in men; age, body mass index, grip strength, alcohol drinking, current smoking, exercise, and menopause in women) showed that serum ucOC concentrations were negatively significantly correlated with all QUS parameters in women. Serum ucOC concentrations were not correlated with them in men. CONCLUSIONS: Vitamin K deficiency, evaluated with higher serum ucOC, was correlated with poor bone status in women.
Asunto(s)
Densidad Ósea , Osteocalcina/sangre , Ultrasonografía , Deficiencia de Vitamina K/diagnóstico , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Japón , Masculino , Persona de Mediana Edad , Factores SexualesRESUMEN
The cardinal biological role of vitamin K is to act as cofactor for the carboxylation of a number of vitamin K-dependent proteins, some of which are essential for coagulation, bone formation and prevention of vascular calcification. Functional vitamin K deficiency is common and severe among dialysis patients and has garnered attention as a modifiable risk factor in this population. However, no single biochemical parameter can adequately assess vitamin K status. For each biological function of vitamin K, the degree of carboxylation of the relevant vitamin K-dependent protein most accurately reflects vitamin K status. Dephosphorylated uncarboxylated matrix Gla protein (dp-ucMGP) is the best biomarker for vascular vitamin K status when cardiovascular endpoints are studied. Dp-ucMGP levels are severely elevated in haemodialysis patients and correlate with markers of vascular calcification and mortality in some but not all studies. The aetiology of vitamin K deficiency in haemodialysis is multifactorial, including deficient intake, uraemic inhibition of the vitamin K cycle and possibly interference of vitamin K absorption by phosphate binders. The optimal vitamin K species, dose and duration of supplementation to correct vitamin K status in dialysis patients are unknown. Dp-ucMGP levels dose-proportionally decrease with supraphysiological vitamin K2 supplementation, but do not normalize even with the highest doses. In the general population, long-term vitamin K1 or K2 supplementation has beneficial effects on cardiovascular disease, bone density and fracture risk, and insulin resistance, although some studies reported negative results. In haemodialysis patients, several trials on the effects of vitamin K on surrogate markers of vascular calcification are currently ongoing.
Asunto(s)
Suplementos Dietéticos , Diálisis Renal/efectos adversos , Deficiencia de Vitamina K , Vitamina K/uso terapéutico , Vitaminas/uso terapéutico , Biomarcadores/sangre , Humanos , Estudios Longitudinales , Factores de Riesgo , Vitamina K/análisis , Vitamina K 1/uso terapéutico , Vitamina K 2/análisis , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/terapiaRESUMEN
BACKGROUND: Matrix Gla protein (MGP) is an extrahepatic protein that is dependent on glutamate carboxylation, a vitamin K-dependent process. Its dysfunctional form, desphospho-uncarboxylated-MGP, has been associated with increased arterial calcification and stiffness. The aim of this study was to measure the degree of postoperative carboxylation of MGP and two other Gla proteins in patients scheduled for abdominal or orthopaedic surgery. METHODS: Forty patients undergoing abdominal or orthopaedic surgery were included. Blood samples were collected preoperatively and four days after the surgery. Desphospho-carboxylated MGP (dp-cMGP), desphospho-uncarboxylated MGP (dp-ucMGP), carboxylated osteocalcin (OC) (cOC), uncarboxylated OC (ucOC), and uncarboxylated prothrombin (PIVKA-II) were analysed. RESULTS: Preoperatively, 29 patients had dp-ucMGP levels above the reference values. Patients with pre-existing cardiovascular comorbidities had higher dp-ucMGP preoperatively compared with patients with no record of cardiovascular disease. Postoperatively, this number increased to 36 patients, and median dp-ucMGP levels increased (p < 0.0001) and correlated to a PIVKA-II increase (r = 0.44). On the other hand, dp-cMGP levels did not significantly alter. Decreased levels of ucOC and cOC were seen after surgery (p = 0.017 and p = 0.0033, respectively). Comorbidities, possible nutritional defects, and complications affecting Gla protein activity and function were identified. CONCLUSIONS: Dp-ucMGP was high preoperatively, and had further increased postoperatively. This pattern was linked to several comorbidities, possible nutritional defects, and postoperative complications, which motivates further research about potential interactions between perioperative corrective treatments with vitamin K supplements, cardiovascular biomarkers, and incidents of stroke and myocardial infarction events.
Asunto(s)
Abdomen/cirugía , Proteínas de Unión al Calcio/sangre , Enfermedades Cardiovasculares/etiología , Proteínas de la Matriz Extracelular/sangre , Procedimientos Ortopédicos/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Enfermedades Cardiovasculares/sangre , Enfermedades Cardiovasculares/diagnóstico , Comorbilidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estado Nutricional , Osteocalcina/sangre , Fosforilación , Estudios Prospectivos , Precursores de Proteínas/sangre , Protrombina , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo , Resultado del Tratamiento , Regulación hacia Arriba , Deficiencia de Vitamina K/sangre , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/etiología , Proteína Gla de la MatrizRESUMEN
INTRODUCTION: Zellweger spectrum disorders (ZSDs) are caused by an impairment of peroxisome biogenesis, resulting in multiple metabolic abnormalities. This leads to a range of symptoms, including hepatic dysfunction and coagulopathy. This study evaluated the incidence and severity of coagulopathy and the effect of vitamin K supplementation orally and IV in ZSD. METHODS: Data were retrospectively retrieved from the medical records of 30 ZSD patients to study coagulopathy and the effect of vitamin K orally on proteins induced by vitamin K absence (PIVKA-II) levels. Five patients from the cohort with a prolonged prothrombin time, low factor VII, and elevated PIVKA-II levels received 10 mg of vitamin K IV. Laboratory results, including thrombin generation, at baseline and 72 h after vitamin K administration were examined. RESULTS: In the retrospective cohort, four patients (13.3%) experienced intracranial bleedings and 14 (46.7%) reported minor bleeding. No thrombotic events occurred. PIVKA-II levels decreased 38% after start of vitamin K therapy orally. In the five patients with a coagulopathy, despite treatment with oral administration of vitamin K, vitamin K IV caused an additional decrease (23%) of PIVKA-II levels and increased thrombin generation. CONCLUSION: Bleeding complications frequently occur in ZSD patients due to liver disease and vitamin K deficiency. Vitamin K deficiency is partly corrected by vitamin K supplementation orally, and vitamin K administered IV additionally improves vitamin K status, as shown by further decrease of PIVKA-II and improved thrombin generation.
Asunto(s)
Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Coagulación Sanguínea/efectos de los fármacos , Suplementos Dietéticos , Hemorragia/tratamiento farmacológico , Deficiencia de Vitamina K/tratamiento farmacológico , Vitamina K/administración & dosificación , Síndrome de Zellweger/tratamiento farmacológico , Administración Intravenosa , Administración Oral , Adolescente , Biomarcadores/sangre , Trastornos de la Coagulación Sanguínea/sangre , Trastornos de la Coagulación Sanguínea/diagnóstico , Trastornos de la Coagulación Sanguínea/epidemiología , Niño , Femenino , Hemorragia/sangre , Hemorragia/diagnóstico , Hemorragia/epidemiología , Humanos , Incidencia , Masculino , Países Bajos/epidemiología , Proyectos Piloto , Prueba de Estudio Conceptual , Estudios Prospectivos , Precursores de Proteínas/sangre , Protrombina , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Deficiencia de Vitamina K/sangre , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/epidemiología , Adulto Joven , Síndrome de Zellweger/sangre , Síndrome de Zellweger/diagnóstico , Síndrome de Zellweger/epidemiologíaRESUMEN
BACKGROUND & AIMS: Vitamin K acts as a coenzyme in the γ-carboxylation of vitamin K-dependent proteins, including coagulation factors, osteocalcin, matrix Gla protein (MGP), and the growth arrest-specific 6 (GAS6) protein. Osteocalcin is a key factor for bone matrix formation. MGP is a local inhibitor of soft tissue calcification. GAS6 activity prevents the apoptosis of vascular smooth muscle cells. Few data on vitamin K intake in chronic kidney disease patients and no data in patients on a Mediterranean diet are available. In the present study, we evaluate the dietary intake of vitamin K1 in a cohort of patients undergoing haemodialysis. METHODS: In this multi-centre controlled observational study, data were collected from 91 patients aged >18 years on dialysis treatment for at least 12 months and from 85 age-matched control subjects with normal renal function. Participants completed a food journal of seven consecutive days for the estimation of dietary intakes of macro- and micro-nutrients (minerals and vitamins). RESULTS: Compared to controls, dialysis patients had a significant lower total energy intake, along with a lower dietary intake of proteins, fats, carbohydrates, fibres, and of all the examined minerals (Ca, P, Fe, Na, K, Zn, Cu, and Mg). With the exception of vitamin B12, vitamins intake followed a similar pattern, with a lower intake in vitamin A, B1, B2, C, D, E, folates, K1 and PP. These finding were confirmed also when normalized for total energy intake or for body weight. In respect to the adequate intakes recommended in the literature, the prevalence of a deficient vitamin K intake was very high (70-90%) and roughly double than in controls. Multivariate logistic model identified vitamin A and iron intake as predictors of vitamin K deficiency. CONCLUSIONS: Haemodialysis patients had a significantly low intake in vitamin K1, which could contribute to increase the risk of bone fractures and vascular calcifications. Since the deficiency of vitamin K intake seems to be remarkable, dietary counselling to HD patients should also address the adequacy of vitamin K dietary intake and bioavailability. Whether diets with higher amounts of vitamin K1 or vitamin K supplementation can improve clinical outcomes in dialysis patients remains to be demonstrated.
Asunto(s)
Dieta , Diálisis Renal , Insuficiencia Renal Crónica/sangre , Vitamina K 1/administración & dosificación , Anciano , Índice de Masa Corporal , Estudios de Casos y Controles , Carbohidratos de la Dieta/administración & dosificación , Grasas de la Dieta/administración & dosificación , Proteínas en la Dieta/administración & dosificación , Femenino , Humanos , Masculino , Micronutrientes/administración & dosificación , Persona de Mediana Edad , Evaluación Nutricional , Estado Nutricional , Prevalencia , Ingesta Diaria Recomendada , Insuficiencia Renal Crónica/tratamiento farmacológico , Estudios Retrospectivos , Vitamina K 1/sangre , Deficiencia de Vitamina K/sangre , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/tratamiento farmacológico , Circunferencia de la CinturaRESUMEN
With the discovery that vitamin K-dependent matrix Gla-protein (MGP) is a strong and modifiable factor in the prevention of arterial calcification, vitamin K was put forward as novel treatment option in cardiovascular disease. The vasculoprotective properties of vitamin K are in part based on the ability to improve gamma-glutamylcarboxylation of MGP, which is a prerequisite for MGP as a calcification inhibitor. Data from experimental animal models reveal that high intake of vitamin K can prevent and even reverse vascular calcifications. In addition, clinical data demonstrate that prescription of vitamin K antagonists for long-term oral anticoagulant therapy accelerates vascular calcification. However, controlled data from randomized prospective vitamin K interventional trials are lacking, thereby weakening a general recommendation for supplementation. The present article summarizes our current knowledge on the association between vitamin K and cardiovascular health. Additionally, we focus on an outlook on important ongoing prospective vitamin K intervention studies. These studies address the issues whether vitamin K substitution helps modifying relevant cardiovascular surrogates such as vascular calcification and whether non-vitamin K oral anticoagulants provide an alternative to support cardiovascular health benefits. So research about cardiovascular protection by vitamin K is an evolving field in which we expect a boost of novel and relevant evidence shortly.
Asunto(s)
Suplementos Dietéticos , Enfermedades Vasculares/prevención & control , Vitamina K/uso terapéutico , Animales , Anticoagulantes/efectos adversos , Aterosclerosis/epidemiología , Aterosclerosis/metabolismo , Aterosclerosis/prevención & control , Humanos , Osteocalcina/metabolismo , Factores Protectores , Medición de Riesgo , Factores de Riesgo , Resultado del Tratamiento , Calcificación Vascular/epidemiología , Calcificación Vascular/metabolismo , Calcificación Vascular/prevención & control , Enfermedades Vasculares/diagnóstico , Enfermedades Vasculares/epidemiología , Enfermedades Vasculares/metabolismo , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/tratamiento farmacológico , Deficiencia de Vitamina K/epidemiologíaRESUMEN
Vitamin K deficiency is associated with malnutrition in some complications, such as hyperemesis gravidarum, active gastrointestinal diseases, and psychological disorders. Maternal vitamin K deficiency can cause fetal bleeding, in particular, fetal intracranial hemorrhage. Although fetal hemorrhage is uncommon, severe damage to the fetus may be inevitable. We describe a pregnant woman with vitamin K deficiency possibly due to hyperemesis gravidarum. The patient was treated for the deficiency, and no fetal or neonatal hemorrhagic diseases were manifested.
Asunto(s)
Coagulación Sanguínea , Sangre Fetal , Hiperemesis Gravídica/complicaciones , Complicaciones Hematológicas del Embarazo/etiología , Deficiencia de Vitamina K/etiología , Administración Oral , Adulto , Pruebas de Coagulación Sanguínea , Suplementos Dietéticos , Femenino , Humanos , Hiperemesis Gravídica/diagnóstico , Nacimiento Vivo , Fenómenos Fisiologicos Nutricionales Maternos , Estado Nutricional , Apoyo Nutricional , Embarazo , Complicaciones Hematológicas del Embarazo/sangre , Complicaciones Hematológicas del Embarazo/diagnóstico , Complicaciones Hematológicas del Embarazo/terapia , Resultado del Tratamiento , Vitamina K/administración & dosificación , Deficiencia de Vitamina K/sangre , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/terapiaRESUMEN
Objetivos: Se admite hoy en día que la vitamina K tiene un papel importante en la salud ósea. Es necesaria para la gamma-carboxilación de la osteocalcina (la proteína no colágena más importante en el hueso), consiguiendo que la osteocalcina funcione. Hay dos formas importantes de la vitamina K (vitamina K1 y vitamina K2), que provienen de diferentes fuentes y tienen diferentes actividades biológicas. Estudios epidemiológicos sugieren que una dieta con niveles altos de vitamina K se asocia con un menor riesgo de fracturas de cadera en hombres ancianos y mujeres. Sin embargo, ensayos clínicos controlados y aleatorizados, realizados con suplementos de vitamina K1 o K2 en la población blanca, no muestran un aumento en la densidad mineral ósea (DMO) en la mayoría de las diferentes partes del esqueleto. Los suplementos con vitamina K1 y K2 pueden reducir el riesgo de fractura, pero los ensayos clínicos que incluyen las fracturas como resultado final tienen limitaciones metodológicas, por lo que se necesitarían ensayos clínicos con mayor número de pacientes y mejor diseñados para comprobar la eficacia de la vitamina K1 y K2 en las fracturas. Como conclusión, podríamos decir que actualmente no existe una evidencia suficiente para recomendar el uso rutinario de suplementos de vitamina K para la prevención de la osteoporosis y las fracturas en mujeres postmenopáusicas (AU)
Objetives: Nowadays it is recognised that vitamin K plays an important role in bone health. It is necessary for the gamma-carboxylation of osteocalcin (the most important non-collagen protein in the bone), making the osteocalcin function. There are two important forms of vitamin K (vitamin K1 and vitamin K2), which come from different sources and have different biological activity. Epidemiological studies suggest that a diet with high levels of vitamin K is associated with a lower risk of hip fractures in older men and in women. However, controlled randomised clinical trials, carried out with supplements of vitamin K1 or K2 in the white population do not show an increase in bone mineral density (BMD) in most of the different areas of the skeleton. Supplementation with vitamin K1 and K2 may reduce the risk of fracture, but the clinical trials which include fractures as a final result have methodological limitations, so clinical trials with greater numbers of patients, and which are better designed, would be needed in order to prove the efficacy of vitamin K1 and K2 in relation to fractures. In conclusion, we may say that there is currently insufficient evidence to recommend the routine use of vitamin K for the prevention of osteoporosis and fractures in postmenopausal women (AU)
Asunto(s)
Humanos , Enfermedades Óseas Endocrinas/prevención & control , Vitamina K/uso terapéutico , Osteocalcina/fisiología , Deficiencia de Vitamina K/diagnóstico , Densidad Ósea/fisiología , Vitamina K 2/análisis , Osteoporosis/prevención & control , Fracturas Osteoporóticas/prevención & controlRESUMEN
BACKGROUND: Vitamin K modulates calcification by activating calcification inhibitors such as matrix Gla protein (MGP). In kidney transplant recipients, vitamin K insufficiency is common, but implications for long-term outcomes are unclear. STUDY DESIGN: Single-center observational study with a longitudinal design. SETTING & PARTICIPANTS: 518 stable kidney transplant recipients; 56% men; mean age, 51±12 (SD) years; and a median of 6 (IQR, 3-12) years after kidney transplantation. FACTOR: Plasma desphosphorylated-uncarboxylated MGP (dp-ucMGP) levels, reflecting vitamin K status. OUTCOMES: All-cause mortality and transplant failure. RESULTS: At inclusion, median dp-ucMGP level was 1,038 (IQR, 733-1,536) pmol/L, with 473 (91%) patients having vitamin K insufficiency (defined as dp-ucMGP>500pmol/L). During a median follow-up of 9.8 (IQR, 8.5-10.2) years, 152 (29%) patients died and 54 (10%) developed transplant failure. Patients in the highest quartile of dp-ucMGP were at considerably higher mortality risk compared with patients in the lowest quartile (HR, 3.10; 95% CI, 1.87-5.12; P for trend<0.001; P for quartile 1 [Q1] vs Q4<0.001). After adjustment for potential confounders, including kidney function and exclusion of patients treated with a vitamin K antagonist, this association remained significant. Patients in the highest quartile also were at higher risk of developing transplant failure (HR, 2.61; 95% CI, 1.22-5.57; P for trend=0.004; P for Q1 vs Q4=0.01), but this association was lost after adjustment for baseline kidney function (HR, 1.20; 95% CI, 0.52-2.75; P for trend=0.6; P for Q1 vs Q4=0.7). LIMITATIONS: Although MGP exists as various species, only dp-ucMGP was measured. No data were available for vascular calcification as an intermediate end point. CONCLUSIONS: Vitamin K insufficiency, that is, a high circulating level of dp-ucMGP, is highly prevalent in stable kidney transplant recipients and is associated independently with increased risk of mortality. Future studies should address whether vitamin K supplementation may lead to improved outcomes after kidney transplantation.
Asunto(s)
Trasplante de Riñón/mortalidad , Deficiencia de Vitamina K/sangre , Deficiencia de Vitamina K/mortalidad , Vitamina K/sangre , Adulto , Anciano , Biomarcadores/sangre , Proteínas de Unión al Calcio/sangre , Estudios de Cohortes , Proteínas de la Matriz Extracelular/sangre , Femenino , Estudios de Seguimiento , Humanos , Trasplante de Riñón/tendencias , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Mortalidad/tendencias , Deficiencia de Vitamina K/diagnóstico , Proteína Gla de la MatrizRESUMEN
A 61-year old woman with atrial fibrillation developed macrohaematuria during anticoagulant treatment with a direct oral factor Xa inhibitor for stroke prevention. Abnormal results of coagulation assays were first interpreted as an effect of the anticoagulant. However, upon further testing diagnosis of vitamin K deficiency was established. After vitamin K supplementation, coagulation tests normalized and macrohaematuria disappeared. Treatment with broad spectrum antibiotics for urinary tract infection was finally established as a rare cause for vitamin K deficiency in the patient.
Asunto(s)
Antibacterianos/efectos adversos , Hematuria/inducido químicamente , Hematuria/etiología , Fenprocumón/administración & dosificación , Deficiencia de Vitamina K/tratamiento farmacológico , Deficiencia de Vitamina K/etiología , Vitamina K/uso terapéutico , Administración Oral , Anticoagulantes/administración & dosificación , Reacciones Falso Positivas , Femenino , Hematuria/prevención & control , Humanos , Persona de Mediana Edad , Resultado del Tratamiento , Vitamina K/antagonistas & inhibidores , Deficiencia de Vitamina K/diagnósticoRESUMEN
We report a case of fat-soluble vitamin deficiency in a 14-year old boy who had chronic duodenal obstruction. He presented with periodic unexplained bleeding tendency. The laboratory results showed positive fat globules in stool and prolonged prothrombin time. His further investigation revealed low plasma vitamin A and undetectable plasma vitamin E. After parenteral vitamin K and oral vitamin A and E supplement, these abnormalities resolved although he still had absent knee jerk. We propose that fat malabsorption and fat-soluble vitamin deficiency can occur after prolonged duodenal obstruction that induce bacterial overgrowth following by bile acid deconjugation. Despite very few case reports, screening for fat malabsorption and fat-soluble vitamin deficiency might be warranted in patients with chronic small bowel obstruction.
Asunto(s)
Obstrucción Duodenal/cirugía , Derivación Gástrica/efectos adversos , Hemorragia/etiología , Complicaciones Posoperatorias/etiología , Esteatorrea/fisiopatología , Deficiencia de Vitamina K/fisiopatología , Adolescente , Diagnóstico Tardío , Hemorragia/prevención & control , Humanos , Infusiones Parenterales , Masculino , Complicaciones Posoperatorias/prevención & control , Reoperación/efectos adversos , Esteatorrea/etiología , Resultado del Tratamiento , Vitamina K/administración & dosificación , Vitamina K/uso terapéutico , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/tratamiento farmacológico , Deficiencia de Vitamina K/etiologíaRESUMEN
BACKGROUND: As the vitamin K content of human milk is low and the newborn infant's stores of vitamin K are small, vitamin K deficiency with hemorrhage in the newborn is a worldwide problem. Proteins Induced by Vitamin K Absence (PIVKA-II) are the inactive under-γ-carboxylated forms of vitamin K-dependent clotting factors and they could be useful in predicting subclinical vitamin K deficiency (VKD). OBJECTIVES: To demonstrate that PIVKA-II are earlier markers of subclinical VKD than Prothrombin time (PT) in exclusively breast-fed newborns. METHODS: A prospective, controlled, randomized study, including 53 term newborns receiving vitamin K prophylaxis (0.5 mg i.m.) at birth, was performed. At 30 days newborns were divided into three groups (G) receiving respectively: 25 µg/die of vitamin K (G I), 12 µg/die (G II) or placebo (G III). PIVKA-II and PT were measured on 30th and 90th days of life. RESULTS: G III and GII showed a significant increase in PIVKA-II from 30 to 90 days of life respectively from 2.6 to 4.7 (p = 0.001) and from 2.3 to 3.5 (p < 0.001). No significant changes were found in GI. PT showed no significant changes among groups. CONCLUSIONS: PT is a less sensitive marker than PIVKA II. Oral supplementation with 25 µg/die avoids an increase of PIVKA-II. Despite increased PIVKA-II do not mean an impending occurrence of bleeding, they highlight a subclinical VKD and its relative risk.
Asunto(s)
Biomarcadores/sangre , Precursores de Proteínas/sangre , Nacimiento a Término/sangre , Deficiencia de Vitamina K/diagnóstico , Enfermedades Asintomáticas , Biomarcadores/análisis , Suplementos Dietéticos , Diagnóstico Precoz , Sangre Fetal/química , Humanos , Lactante , Recién Nacido , Precursores de Proteínas/análisis , Precursores de Proteínas/fisiología , Protrombina/análisis , Protrombina/fisiología , Tiempo de Protrombina , Factores de Tiempo , Vitamina K/administración & dosificación , Deficiencia de Vitamina K/sangre , Deficiencia de Vitamina K/tratamiento farmacológicoRESUMEN
Relatively little is known about the vitamin K status and requirements in term and preterm infants, though hemorrhagic disease of the newborn infant continues to be a worldwide problem. This brief review of vitamin K metabolism, vitamin K dependent proteins, and the vitamin K cycle covers some new thoughts about the importance of vitamin K to human health including the preterm infant. A review of perinatal vitamin K metabolism concludes that little vitamin K actually crosses the placenta from mother to infant. The neonatal sources of vitamin K are generally limited to the vitamin K prophylaxis given at the time of birth, dietary sources, and questionable amounts from vitamin K present in the intestinal tract synthesized from bacteria. Preterm infants receive large quantities of vitamin K from prophylaxis, TPN solutions, infant formula and breast milk fortifiers. Thus, vitamin serum concentration in preterm infants is up to one hundred times higher than those found in adults and 10-20 times those found in term formula-fed infants. Though no toxicity has been reported, the elevation of epoxide reductase (VKOR) from the vitamin K cycle found in the serum of preterm infants is worthy of additional study. PIVKA-II (abnormal prothrombin) is not a reliable indicator of vitamin K deficiency in preterm or term infants.
Asunto(s)
Vitamina K/fisiología , Vitamina K/uso terapéutico , Adulto , Humanos , Fenómenos Fisiológicos Nutricionales del Lactante , Recién Nacido/sangre , Modelos Biológicos , Vitamina K/efectos adversos , Vitamina K/metabolismo , Deficiencia de Vitamina K/sangre , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/tratamiento farmacológicoRESUMEN
Nutritional deficiencies have always been a major consideration in pediatrics. Although the classic forms of many of the well-documented nutritional deficiencies are memorized during training as a physician, nutritional deficiencies that can occur in otherwise asymptomatic normally growing children are often overlooked. The two most common deficiencies seen in children who are growing normally are iron and vitamin D deficiencies. These deficiencies are surprisingly common and can have a significant impact on the overall health of a child. This article reviews these nutritional deficiencies and other less commonly seen deficiencies in children who are otherwise growing normally.
Asunto(s)
Avitaminosis/diagnóstico , Avitaminosis/terapia , Desarrollo Infantil , Desnutrición/diagnóstico , Desnutrición/terapia , Oligoelementos/deficiencia , Anemia Ferropénica/diagnóstico , Anemia Ferropénica/terapia , Deficiencia de Ácido Ascórbico/diagnóstico , Deficiencia de Ácido Ascórbico/terapia , Avitaminosis/dietoterapia , Avitaminosis/tratamiento farmacológico , Calcio/deficiencia , Niño , Cobre/deficiencia , Humanos , Fórmulas Infantiles/química , Fórmulas Infantiles/normas , Yodo/deficiencia , Desnutrición/dietoterapia , Desnutrición/tratamiento farmacológico , Raquitismo/diagnóstico , Raquitismo/terapia , Selenio/deficiencia , Estados Unidos , Deficiencia de Vitamina A/diagnóstico , Deficiencia de Vitamina A/terapia , Deficiencia de Vitamina B/diagnóstico , Deficiencia de Vitamina B/terapia , Deficiencia de Vitamina D/diagnóstico , Deficiencia de Vitamina D/terapia , Deficiencia de Vitamina E/diagnóstico , Deficiencia de Vitamina E/terapia , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/terapia , Zinc/deficienciaRESUMEN
Vitamin K (as phylloquinone and menaquinones) is an essential cofactor for the conversion of peptide-bound glutamate to gamma-carboxy glutamic acid (Gla) residues in a number of specialized Gla-containing proteins. The only unequivocal deficiency outcome is a bleeding syndrome caused by an inability to synthesize active coagulation factors II, VII, IX, and X, although there is growing evidence for roles for vitamin K in bone and vascular health. An adult daily intake of about 100 microg of phylloquinone is recommended for the maintenance of hemostasis. Traditional coagulation tests for assessing vitamin K status are nonspecific and insensitive. Better tests include measurements of circulating vitamin K and inactive proteins such as undercarboxylated forms of factor II and osteocalcin to assess tissue and functional status, respectively. Common risk factors for vitamin K deficiency in the hospitalized patient include inadequate dietary intakes, malabsorption syndromes (especially owing to cholestatic liver disease), antibiotic therapy, and renal insufficiency. Pregnant women and their newborns present a special risk category because of poor placental transport and low concentrations of vitamin K in breast milk. Since 2000, the Food and Drug Administration has mandated that adult parenteral preparations should provide a supplemental amount of 150 microg phylloquinone per day in addition to that present naturally, in variable amounts, in the lipid emulsion. Although this supplemental daily amount is probably beneficial in preventing vitamin K deficiency, it may be excessive for patients taking vitamin K antagonists, such as warfarin, and jeopardize their anticoagulant control. Natural forms of vitamin K have no proven toxicity.